$0.77
2.37%
Nasdaq, Sep 29, 04:00 pm EDT.
ISIN
US03836J1025
Symbol
APRE

Aprea Therapeutics Inc Stock price

$0.77
-0.03 3.80% 1M
+0.03 4.14% 6M
-0.08 9.78% YTD
-0.74 49.03% 1Y
-3.40 81.53% 3Y
-101.03 99.24% 5Y
-409.23 99.81% 10Y
-409.23 99.81% 20Y
Nasdaq, Closing price Tue, Sep 29 2026
+0.02 2.37%
ISIN
US03836J1025
Symbol
APRE
Industry

Is Aprea Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$9.7m
Enterprise Value
$-31.5m
Net debt
positive
Cash
$41.2m
Shares outstanding
12.4m
Valuation (TTM | estimate)
P/E
negative
P/S
969.0 | -
EV/Sales
negative | -
EV/FCF
2.6
P/B
0.3
Financial Health
Equity Ratio
82.7%
Return on Equity
-95.7%
ROCE
-33.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.0k | $0.0
EBITDA
$-13.2m
EBIT
$-13.2m
Net Income
$-12.3m
Free Cash Flow
$-12.2m
Growth (TTM | estimate)
Revenue
-98.8% | -100.0%
EBITDA
10.7%
EBIT
10.7%
Net Income
11.1%
Free Cash Flow
4.4%
Margin
Gross
-
EBITDA
-253,867.3%
EBIT
-254,290.4%
Net
-236,678.9%
Free Cash Flow
-234,296.2%
More
EPS
$-0.2
FCF per Share
$-1.0
Short interest
4.8%
Employees
8
Rev per Employee
$40.0k

Aprea Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Aprea Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Aprea Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Aprea Therapeutics Inc

Jun '26
+/-
%
0.01 0.01
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.51 6.51
8% 8%
65,100%
- Research and Development Expense 6.72 6.72
30% 30%
67,200%
-13 -13
11% 11%
-132,000%
- Depreciation and Amortization 0.02 0.02
0% 0%
200%
EBIT (Operating Income) EBIT -13 -13
11% 11%
-132,231%
Net Profit -12 -12
11% 11%
-123,100%

In millions USD.

Don't miss a Thing! We will send you all news about Aprea Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aprea Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
about one month ago
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
Neutral
GlobeNewsWire
●
about 2 months ago
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances
Neutral
GlobeNewsWire
●
2 months ago
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051 Enrollment in ACESOT-1051 is accelerating as the Company advances dose escalation and amasses the clinical data needed to inform dose selection and subsequent development Aprea...
More Aprea Therapeutics Inc News

Company Profile

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.

Head office United States
CEO Dr. Gilad
Employees 8
Founded 2002
Website www.aprea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today